MX356727B - Formulaciones de liberacion modificada de viloxacina. - Google Patents
Formulaciones de liberacion modificada de viloxacina.Info
- Publication number
- MX356727B MX356727B MX2014009528A MX2014009528A MX356727B MX 356727 B MX356727 B MX 356727B MX 2014009528 A MX2014009528 A MX 2014009528A MX 2014009528 A MX2014009528 A MX 2014009528A MX 356727 B MX356727 B MX 356727B
- Authority
- MX
- Mexico
- Prior art keywords
- viloxazine
- modified release
- release formulations
- formulations
- disclosed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261596458P | 2012-02-08 | 2012-02-08 | |
| PCT/US2013/025121 WO2013119794A1 (en) | 2012-02-08 | 2013-02-07 | Modified release formulations of viloxazine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014009528A MX2014009528A (es) | 2014-11-25 |
| MX356727B true MX356727B (es) | 2018-06-12 |
Family
ID=47741312
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014009528A MX356727B (es) | 2012-02-08 | 2013-02-07 | Formulaciones de liberacion modificada de viloxacina. |
| MX2023003000A MX2023003000A (es) | 2012-02-08 | 2014-08-07 | Formulaciones de liberacion modificada de viloxacina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003000A MX2023003000A (es) | 2012-02-08 | 2014-08-07 | Formulaciones de liberacion modificada de viloxacina. |
Country Status (8)
| Country | Link |
|---|---|
| US (9) | US9358204B2 (enExample) |
| EP (2) | EP4233915A3 (enExample) |
| JP (3) | JP6290100B2 (enExample) |
| AU (4) | AU2013217013B2 (enExample) |
| CA (1) | CA2864088C (enExample) |
| ES (1) | ES2950875T3 (enExample) |
| MX (2) | MX356727B (enExample) |
| WO (1) | WO2013119794A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2735934C (en) | 2008-09-05 | 2014-01-07 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (adhd) |
| MX356727B (es) * | 2012-02-08 | 2018-06-12 | Supernus Pharmaceuticals Inc | Formulaciones de liberacion modificada de viloxacina. |
| IT201800011125A1 (it) * | 2018-12-14 | 2020-06-14 | Dpl Pharma S P A | Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico |
| US20240041893A1 (en) * | 2023-10-03 | 2024-02-08 | Innovate Therapeutics Llc | An Extended-Release Pharmaceutical Formulation of Viloxazine And Process For Preparation Thereof |
| WO2025135797A1 (ko) * | 2023-12-18 | 2025-06-26 | 주식회사 아스트로젠 | (s)-빌록사진 또는 이의 염의 개선된 제조 방법 |
| WO2025210464A1 (en) * | 2024-04-04 | 2025-10-09 | Biophore India Pharmaceuticals Pvt. Ltd | Modified release formulations of viloxazine |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1138405A (en) * | 1966-12-28 | 1969-01-01 | Ici Ltd | Morpholine derivatives |
| FR2453639A1 (fr) * | 1979-04-09 | 1980-11-07 | Sanofi Sa | Composition medicamenteuse a liberation programmee immediate-retard a base de naftidrofuryl |
| US4260606A (en) | 1979-07-19 | 1981-04-07 | A. H. Robins Company, Inc. | 3-Methyleneazetidine derivatives |
| US5658590A (en) | 1995-01-11 | 1997-08-19 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| US5558879A (en) * | 1995-04-28 | 1996-09-24 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water soluble drugs in which a passageway is formed in situ |
| US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
| DE19830201A1 (de) | 1998-07-07 | 2000-01-13 | Boehringer Ingelheim Pharma | Mittel mit antidepressiver Wirkung |
| WO2000006162A1 (de) | 1998-07-27 | 2000-02-10 | Boehringer Ingelheim Pharma Kg | Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum |
| EP1353675A2 (en) | 2001-01-02 | 2003-10-22 | PHARMACIA & UPJOHN COMPANY | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
| JP4280074B2 (ja) * | 2001-04-25 | 2009-06-17 | 大正製薬株式会社 | マルチプルユニット型徐放性錠剤 |
| SE0102887D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
| US20060121106A1 (en) * | 2003-02-21 | 2006-06-08 | Janez Kerc | Therapeutic system comprising amoxicillin and clavulanic acid |
| DE10353196A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
| US7119031B2 (en) * | 2004-06-28 | 2006-10-10 | Micron Technology, Inc. | Methods of forming patterned photoresist layers over semiconductor substrates |
| DE102004035938A1 (de) * | 2004-07-23 | 2006-02-16 | Röhm GmbH & Co. KG | Verfahren zur Herstellung von überzogenen Arzneiformen mit stabilem Wirkstofffreigabeprofil |
| US7288347B2 (en) | 2004-08-31 | 2007-10-30 | Xerox Corporation | Method of applying spot varnish to xerographic image and emulsion aggregation toners for use therein |
| JP2008536929A (ja) * | 2005-04-18 | 2008-09-11 | ルビコン・リサーチ・ピーヴィーティー・エルティーディー | 生体強化組成物 |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| WO2007026219A2 (en) | 2005-08-31 | 2007-03-08 | Pfizer Products Inc. | Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions |
| US20090041844A1 (en) * | 2006-02-10 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Modified Release Formulation |
| PL2457563T3 (pl) * | 2006-05-09 | 2017-09-29 | Mallinckrodt Llc | Stałe postacie dawkowania o zmodyfikowanym uwalnianiu rzędu zerowego |
| MX2009001711A (es) * | 2006-11-17 | 2009-05-08 | Supernus Pharmaceuticals Inc | Formulaciones de liberacion sostenida de topiramato. |
| WO2008122019A1 (en) * | 2007-04-02 | 2008-10-09 | Cypress Biosciences, Inc. | Improving the tolerability of both mirtazapine and reboxetine by using them in combination |
| WO2008157094A1 (en) * | 2007-06-13 | 2008-12-24 | Cypress Bioscience, Inc. | Improving the tolerability of mirtazapine and a second active by using them in combination |
| WO2009073118A1 (en) * | 2007-12-04 | 2009-06-11 | Merck & Co., Inc. | Tryptamine sulfonamides as 5-ht6 antagonists |
| CA2735934C (en) | 2008-09-05 | 2014-01-07 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (adhd) |
| EP2424539A4 (en) | 2009-04-30 | 2012-09-19 | Supernus Pharmaceuticals Inc | PROCESS FOR TREATING DEPRESSION |
| WO2011008298A2 (en) | 2009-07-16 | 2011-01-20 | Nectid, Inc. | Novel axomadol dosage forms |
| CN102548544B (zh) * | 2009-10-09 | 2015-01-21 | 永进药品工业株式会社 | 同时具有速效特性和长效特性的药物组合物 |
| MX356727B (es) * | 2012-02-08 | 2018-06-12 | Supernus Pharmaceuticals Inc | Formulaciones de liberacion modificada de viloxacina. |
-
2013
- 2013-02-07 MX MX2014009528A patent/MX356727B/es active IP Right Grant
- 2013-02-07 CA CA2864088A patent/CA2864088C/en active Active
- 2013-02-07 EP EP23172156.4A patent/EP4233915A3/en active Pending
- 2013-02-07 EP EP13705348.4A patent/EP2812074B1/en active Active
- 2013-02-07 WO PCT/US2013/025121 patent/WO2013119794A1/en not_active Ceased
- 2013-02-07 US US13/761,757 patent/US9358204B2/en active Active
- 2013-02-07 JP JP2014556658A patent/JP6290100B2/ja active Active
- 2013-02-07 AU AU2013217013A patent/AU2013217013B2/en active Active
- 2013-02-07 ES ES13705348T patent/ES2950875T3/es active Active
-
2014
- 2014-08-07 MX MX2023003000A patent/MX2023003000A/es unknown
-
2016
- 2016-05-18 US US15/157,549 patent/US9603853B2/en active Active
- 2016-06-03 US US15/172,955 patent/US9662338B2/en active Active
-
2017
- 2017-05-25 US US15/605,108 patent/US10265319B2/en active Active
- 2017-07-20 AU AU2017206245A patent/AU2017206245B2/en active Active
-
2018
- 2018-02-06 JP JP2018018946A patent/JP6510093B2/ja active Active
-
2019
- 2019-03-08 US US16/297,194 patent/US20190201407A1/en active Pending
- 2019-03-29 JP JP2019066455A patent/JP6832973B2/ja active Active
- 2019-08-16 AU AU2019216707A patent/AU2019216707B2/en active Active
-
2020
- 2020-09-18 AU AU2020233746A patent/AU2020233746B2/en active Active
-
2023
- 2023-08-10 US US18/232,716 patent/US20230381191A1/en not_active Abandoned
-
2025
- 2025-03-28 US US19/093,755 patent/US20250222004A1/en active Pending
- 2025-04-07 US US19/171,852 patent/US20250228859A1/en active Pending
- 2025-08-21 US US19/306,464 patent/US20250367208A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3043824A4 (en) | Modified therapeutic agents and compositions thereof | |
| TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
| WO2013177419A3 (en) | Lipid nanoparticle compositions and methods of making and methods of using the same | |
| TN2012000611A1 (en) | Formulations of rifaximin and uses thereof | |
| MY185016A (en) | Progenitor cells of mesodermal lineage | |
| IN2015DN00127A (enExample) | ||
| PH12015501998A1 (en) | Heterocyclic compounds and their uses | |
| EP3054929A4 (en) | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | |
| MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
| IN2014DN06104A (enExample) | ||
| EP2983681A4 (en) | Therapeutic compositions and uses thereof | |
| MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
| MX365403B (es) | Peptidos y metodos para usarlos. | |
| EP3013364A4 (en) | Tuberculosis compositions and methods of using the same | |
| MX356727B (es) | Formulaciones de liberacion modificada de viloxacina. | |
| EP3057596A4 (en) | Compositions and methods of administering same | |
| MX344189B (es) | Formulaciones de mazindol. | |
| MX2014008390A (es) | Formulaciones de romidepsina y sus usos. | |
| IL246408A0 (en) | Preparations for delayed release of proteins and their uses | |
| EP2945703A4 (en) | ALBU-BCHE FORMULATIONS, PREPARATION THEREOF AND USES THEREOF | |
| MX375224B (es) | Composiciones antitranspirantes y métodos. | |
| AU2012902982A0 (en) | Compositions and methods for the treatment of tuberculosis | |
| HK1229735A1 (en) | Sustained release depot formulations of therapeutic proteins, and uses thereof | |
| IN2013CH02437A (enExample) | ||
| UA80618U (en) | Use of n-steroylethanolamine as radiomodifier |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |